[go: up one dir, main page]

AU2001244399A1 - Gamma-secretase inhibitors - Google Patents

Gamma-secretase inhibitors

Info

Publication number
AU2001244399A1
AU2001244399A1 AU2001244399A AU4439901A AU2001244399A1 AU 2001244399 A1 AU2001244399 A1 AU 2001244399A1 AU 2001244399 A AU2001244399 A AU 2001244399A AU 4439901 A AU4439901 A AU 4439901A AU 2001244399 A1 AU2001244399 A1 AU 2001244399A1
Authority
AU
Australia
Prior art keywords
gamma
secretase inhibitors
secretase
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001244399A
Inventor
Alan John Nadin
Graeme Irvine Stevenson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Original Assignee
Merck Sharp and Dohme Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd filed Critical Merck Sharp and Dohme Ltd
Publication of AU2001244399A1 publication Critical patent/AU2001244399A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001244399A 2000-04-07 2001-04-04 Gamma-secretase inhibitors Abandoned AU2001244399A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0008710 2000-04-07
GBGB0008710.6A GB0008710D0 (en) 2000-04-07 2000-04-07 Therapeutic compounds
PCT/GB2001/001549 WO2001077144A1 (en) 2000-04-07 2001-04-04 Gamma-secretase inhibitors

Publications (1)

Publication Number Publication Date
AU2001244399A1 true AU2001244399A1 (en) 2001-10-23

Family

ID=9889526

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001244399A Abandoned AU2001244399A1 (en) 2000-04-07 2001-04-04 Gamma-secretase inhibitors

Country Status (4)

Country Link
US (1) US6984626B2 (en)
AU (1) AU2001244399A1 (en)
GB (1) GB0008710D0 (en)
WO (1) WO2001077144A1 (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
AU2003299025A1 (en) * 2002-09-17 2004-04-08 K.U. Leuven Research & Development Peptides inhibiting specific cleaving activities of presenilins
BRPI0407597A (en) * 2003-02-18 2006-02-21 Roskamp Res Llc Anti-angiogenic and anti-tumor properties of beta and gamma secretase inhibitors
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
ES2383306T3 (en) 2004-02-03 2012-06-20 The Regents Of The University Of Michigan Compositions for the treatment of breast and pancreas cancer
CA2554779A1 (en) * 2004-02-03 2005-08-18 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
US20060252073A1 (en) * 2005-04-18 2006-11-09 Regents Of The University Of Michigan Compositions and methods for the treatment of cancer
CA2628255C (en) 2005-10-31 2016-04-19 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1998785A4 (en) * 2006-02-21 2009-06-17 Univ Michigan CANCER TREATMENT USING A HEDGEHOG SIGNALING PATH
WO2007103114A2 (en) 2006-03-07 2007-09-13 The Brigham & Women's Hospital, Inc. Notch inhibition in the treatment or prevention of atherosclerosis
US9567396B2 (en) 2006-03-07 2017-02-14 Evonik Degussa Gmbh Notch inhibition in the prevention of vein graft failure
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
EP2094836B1 (en) 2006-11-15 2016-06-08 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
SI2091948T1 (en) 2006-11-30 2012-07-31 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
US8148147B2 (en) 2007-01-24 2012-04-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
JP5930573B2 (en) 2007-03-01 2016-06-15 プロビオドルグ エージー New use of glutaminyl cyclase inhibitors
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
WO2009035522A1 (en) * 2007-09-14 2009-03-19 Albert Einstein College Of Medicine Of Yeshiva University Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease
PL2222636T3 (en) 2007-12-21 2014-04-30 Ligand Pharm Inc Selective androgen receptor modulators (sarms) and uses thereof
JP5809061B2 (en) 2008-11-24 2015-11-10 マサチューセッツ・アイ・アンド・イア・インファーマリー Pathways for producing hair cells
WO2011009064A1 (en) * 2009-07-17 2011-01-20 The J. David Gladstone Institutes Methods of controlling cell proliferation
SG178953A1 (en) 2009-09-11 2012-04-27 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
EP2493497A4 (en) 2009-11-01 2013-07-24 Brigham & Womens Hospital INHIBITION OF NOTCH FOR THE TREATMENT AND PREVENTION OF OBESITY AND METABOLIC SYNDROME
EP2542549B1 (en) 2010-03-03 2016-05-11 Probiodrug AG Inhibitors of glutaminyl cyclase
WO2011110613A1 (en) 2010-03-10 2011-09-15 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
TWI530489B (en) 2011-03-22 2016-04-21 必治妥美雅史谷比公司 Bis(fluoroalkyl)-1,4-benzodiazepine compound
WO2013059302A1 (en) 2011-10-17 2013-04-25 Nationwide Children's Hospital, Inc. Products and methods for aortic abdominal aneurysm
HK1211875A1 (en) 2012-09-07 2016-06-03 Massachusetts Eye & Ear Infirmary Treating hearing loss
WO2014039908A1 (en) 2012-09-07 2014-03-13 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells
US9242941B2 (en) 2012-09-21 2016-01-26 Bristol-Myers Squibb Company Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds
US9273075B2 (en) 2012-09-21 2016-03-01 Bristol-Myers Squibb Company Prodrugs of 1,4-benzodiazepinone compounds
TWI614238B (en) 2012-09-21 2018-02-11 必治妥美雅史谷比公司 Bis(fluoroalkyl)-1,4-benzodiazepine compounds and prodrugs thereof
JP2015529252A (en) 2012-09-21 2015-10-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Fluoroalkyl-1,4-benzodiazepinone compounds
WO2014047370A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Fluoroalkyl dibenzodiazepinone compounds
US9427442B2 (en) 2012-09-21 2016-08-30 Bristol-Myers Squibb Company Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds
CN104854097A (en) 2012-09-21 2015-08-19 百时美施贵宝公司 N-substituted bis(fluoroalkyl)-1,4-benzodiazepinone compounds
JP2015529251A (en) 2012-09-21 2015-10-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Tricyclic heterocyclic compounds as NOTCH inhibitors
CN104797569A (en) 2012-09-21 2015-07-22 百时美施贵宝公司 Substituted 1,5-benzodiazepinone compounds
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
CN105101968A (en) 2013-04-04 2015-11-25 百时美施贵宝公司 Combination therapy for the treatment of proliferative diseases
EP3094323A4 (en) 2014-01-17 2017-10-11 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
CN106488775A (en) 2014-07-11 2017-03-08 基因泰克公司 NOTCH pathway inhibition
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
HK1255694A1 (en) 2015-07-24 2019-08-23 Oncotracker, Inc. Gamma secretase modulators for the treatment of immune system dysfunction
US11185536B2 (en) 2015-12-04 2021-11-30 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
KR20180117628A (en) 2016-01-29 2018-10-29 매사추세츠 아이 앤드 이어 인퍼머리 Expansion and differentiation of inner ear support cells and their use
JP6840774B2 (en) 2016-05-16 2021-03-10 ザ ジェネラル ホスピタル コーポレイション Human airway stem cells in lung epithelial engineering
IL267253B2 (en) 2016-12-16 2023-04-01 Pipeline Therapeutics Inc Methods of treating cochlear synaptopathy
CN110461335A (en) 2017-02-17 2019-11-15 弗雷德哈钦森癌症研究中心 Combination therapy for the treatment of BCMA-related cancers and autoimmune disorders
PL3461819T3 (en) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitors of glutaminyl cyclase
WO2020016377A1 (en) 2018-07-19 2020-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination for treating cancer
WO2020214834A1 (en) 2019-04-19 2020-10-22 Ligand Pharmaceuticals Inc. Crystalline forms and methods of producing crystalline forms of a compound
JP2023520771A (en) 2020-03-26 2023-05-19 シージェン インコーポレイテッド Methods of treating multiple myeloma
US20230416830A1 (en) 2020-11-16 2023-12-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating uveal melanoma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91307A0 (en) * 1988-08-24 1990-03-19 Merck & Co Inc Hiv protease inhibitors and pharmaceutical compositions for the treatment of aids containing them
JPH05208947A (en) * 1991-08-16 1993-08-20 Merck & Co Inc Hiv protease inhibitor having polyether group bonded to n atom of molecular end
WO1994013319A1 (en) * 1992-12-16 1994-06-23 Miles Inc. Cathepsin d is an amyloidogenic protease in alzheimer's disease
US5703129A (en) * 1996-09-30 1997-12-30 Bristol-Myers Squibb Company 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production
DE69913996T2 (en) * 1998-01-27 2004-12-09 Nisshin Seifun Group Inc. Depsipeptides that contain non-natural amino acids

Also Published As

Publication number Publication date
US6984626B2 (en) 2006-01-10
US20030100512A1 (en) 2003-05-29
GB0008710D0 (en) 2000-05-31
WO2001077144A1 (en) 2001-10-18

Similar Documents

Publication Publication Date Title
AU2001244399A1 (en) Gamma-secretase inhibitors
AU2001258771A1 (en) -secretase inhibitors
AU2001296961A1 (en) 17-beta-hydroxysteroid dehydrogenase-ii inhibitors
AU2002219555A1 (en) VLA-4 Inhibitors
AU2001234088A1 (en) TNF-alpha inhibitors
AU2002220241A1 (en) Parb inhibitors
AU2000267458A1 (en) Hypercomputer
AU2002211663A1 (en) Nf-$g(k)b inhibitors
AU2001220246A1 (en) Neckphone
AU2001239310A1 (en) Decahydro-isoquinolines
AU2001247589A1 (en) Non-amidine containing protease inhibitors
AU2001285750A1 (en) Urokinase inhibitors
AU2001258349A1 (en) Bisacylguanidine
AU5248800A (en) Fading inhibitors
AU2002211662A1 (en) Nf-kappab inhibitors
AU2001220281A1 (en) Rollerboard for road-skiing
AU2001258841A1 (en) Heterocyclic compounds
AU2001232245A1 (en) Tnf- alpha inhibitors
AU2002224550A1 (en) Corrosion inhibitors
AU3235100A (en) Prothease inhibitors
AU7957000A (en) Cyclooxygenase-2 expression inhibitors
AU2001262711A1 (en) Cytoprotectors
AU2001268853A1 (en) Biocatalyst inhibitors
AU2001260192A1 (en) Glycinamides
AU6286101A (en) New use